US60770K1079 - Common Stock
MODERNA INC
NASDAQ:MRNA (4/17/2024, 7:13:59 PM)
After market: 103.1 -0.34 (-0.33%)103.44
-0.35 (-0.34%)
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2018-12-07. The firm is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The firm's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). The company has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.
MODERNA INC
200 Technology Sq
Cambridge MASSACHUSETTS 02139
P: 16177146500
CEO: Stephane Bancel
Employees: 3900
Website: https://www.modernatx.com/
These companies have gotten in on AI early and could emerge as winners.
These companies have gotten in on AI early and could emerge as winners.
These stocks have plenty of catalysts ahead.
There's a new reason to believe that their joint projects are going well.
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
Here you can normally see the latest stock twits on MRNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: